FGFR
FGFRs (fibroblast growth factor receptors) are transmembrane tyrosine kinase receptor. It is involved in carcinogenesis and plays an important role in cell differentiation, survival and proliferation etc.
Products for FGFR
- Cat.No. Product Name Information
- GC62291 (Z)-Orantinib (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
- GC33519 2,5-Dihydroxybenzoic acid A benzoic acid with diverse biological activities
- GC15801 ACTB-1003 ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.
- GC32127 Alofanib (RPT835) Alofanib (RPT835) (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2).
- GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.
- GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research.
- GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.
- GC14005 AZD4547 FGFR inhibitor
- GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
- GC10055 BGJ398 An FGFR inhibitor
- GC19075 BLU-554 BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling.
- GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible
- GC10759 CH5183284 (Debio-1347) CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
- GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF
- GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy.
- GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.
- GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.
- GC15217 Danusertib (PHA-739358) A pan-Aurora kinase and Abl inhibitor
- GC19399 Derazantinib Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
- GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
- GC12149 E-3810
- GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.
- GC16519 ENMD-2076 A multi-kinase inhibitor
- GC12145 ENMD-2076 L-(+)-Tartaric acid
- GC19142 Erdafitinib A pan-FGFR tyrosine kinase inhibitor
- GC63395 FGFR-IN-1 FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219).
- GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.
- GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively.
- GC19155 FGFR4-IN-1 FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM.
- GC62602 FGFR4-IN-5 FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.
- GC50051 FIIN 1 hydrochloride FIIN 1 hydrochloride is a potent, irreversible, selective FGFR inhibitor. FIIN 1 hydrochloride binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN 1 hydrochloride are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.
- GC17323 FIIN-2 Irreversible inhibitor of FGFR
- GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
- GN10527 Formononetin
- GN10540 Fumalic acid
- GC64875 Gunagratinib Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer.
- GC19187 H3B-6527 H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice.
-
GC30767
Heparan Sulfate
Heparan sulfate (HS) is a complex, polyanionic polysaccharide ubiquitously expressed on cell surfaces and in the extracellular matrix.
- GC14592 KW 2449 A multi-kinase inhibitor
- GC15454 Lenvatinib (E7080) Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
- GC36438 Lenvatinib mesylate An inhibitor of VEGFR2 and VEGFR3
- GC13848 LY2784544 Potent inhibitor of JAK2
- GC13424 LY2874455 A pan-FGFR inhibitor
- GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
- GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.
- GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib
- GC11705 Nintedanib (BIBF 1120) A VEGFR, FGFR, and PDGFR inhibitor
-
GC36745
Nintedanib esylate
Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .
- GC16028 NVP-BGJ398 phosphate
- GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment.
- GC16327 Pazopanib (GW-786034) A multi-kinase inhibitor
- GC12730 Pazopanib Hydrochloride VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor
- GC44583 PD 089828 PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM).
- GC12049 PD 161570 FGFR inhibitor
- GC17943 PD 173074 Inhibitor of tyrosine kinase activity of fibroblast growth factor receptors
- GC19279 PD-166866 PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM.
- GC32915 Pemigatinib An FGFR inhibitor
- GC31495 PF-05231023 PF-05231023 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
- GC14396 Ponatinib (AP24534) Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
- GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib
- GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values.
- GC32802 PRN1371 An irreversible pan-FGFR inhibitor
-
GC19154
Roblitinib
Roblitinib (FGF-401) is a 1,8-naphthyridine pyridine derivative
- GC34067 Rogaratinib (BAY1163877) Rogaratinib (BAY1163877) (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.
- GC19317 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
- GC12776 SKLB610 An inhibitor of VEGFR2
- GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.
- GC10491 SSR128129E allosteric inhibitor of FGFR1, orally-active
- GC37679 SSR128129E free acid SSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1.
- GC14660 SU 5402 An inhibitor of VEGFR2, FGFR1, and PDGFRβ
- GC61957 SU4984 SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer.
- GC32805 Sulfatinib (HMPL-012) Sulfatinib (HMPL-012) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
- GC19341 SUN11602 SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
- GC49700 Takeda-6d
- GC19156 TAS-120 TAS-120 (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. TAS-120 inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9nM; V5651=1-3nM; N550H=3.6nM; E566G=2.4nM).
- GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
- GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
- GC11622 TG 100801
- GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
- GC16732 TSU-68 (SU6668,Orantinib) TSU-68 (SU6668,Orantinib) (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.
- GC34026 Tyrosine kinase-IN-1 Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.
-
GC70122
Vofatamab
Vofatamab (B-701) is a monoclonal antibody (mAb) that targets FGFR3. Vofatamab blocks the activation of both wild-type and mutated receptors. It is being studied for its potential use in metastatic urothelial carcinoma (MUC).
-
GC70125
Vosoritide acetate
Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that can stimulate the proliferation and differentiation of chondrocytes, promoting bone growth.